請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73941
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳沛隆(Pei-Lung Chen) | |
dc.contributor.author | Meng-Han Chang | en |
dc.contributor.author | 張孟涵 | zh_TW |
dc.date.accessioned | 2021-06-17T08:14:24Z | - |
dc.date.available | 2022-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-14 | |
dc.identifier.citation | 1.Martin, K.R., et al., The genomic landscape of tuberous sclerosis complex. Nat Commun, 2017. 8: p. 15816.
2.Rosset, C., C.B.O. Netto, and P. Ashton-Prolla, TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review. Genet Mol Biol, 2017. 40(1): p. 69-79. 3.Gomez, M.R., History of the tuberous sclerosis complex. Brain Dev, 1995. 17 Suppl: p. 55-7. 4.Miloloza, A., et al., The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum Mol Genet, 2000. 9(12): p. 1721-7. 5.Huang, J. and B.D. Manning, The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J, 2008. 412(2): p. 179-90. 6.Laplante, M. and D.M. Sabatini, mTOR signaling at a glance. J Cell Sci, 2009. 122(Pt 20): p. 3589-94. 7.Hino, O. and T. Kobayashi, Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. Cancer Sci, 2017. 108(1): p. 5-11. 8.Napolioni, V. and P. Curatolo, Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics, 2008. 9(7): p. 475-87. 9.Portocarrero, L.K.L., et al., Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol, 2018. 93(3): p. 323-331. 10.Caban, C., et al., Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet, 2017. 10: p. 1-8. 11.Northrup, H. and D.A. Krueger, Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol, 2013. 49(4): p. 243-54. 12.Northrup, H., et al., Tuberous Sclerosis Complex, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993, University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.: Seattle (WA). 13.Curatolo, P. and R. Moavero, mTOR Inhibitors in Tuberous Sclerosis Complex. Curr Neuropharmacol, 2012. 10(4): p. 404-15. 14.Tran, L.H. and M.L. Zupanc, Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature. Pediatr Neurol, 2015. 53(1): p. 23-30. 15.Zhou, S.F., J.P. Liu, and B. Chowbay, Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev, 2009. 41(2): p. 89-295. 16.Mieulet, V. and R.F. Lamb, Tuberous sclerosis complex: linking cancer to metabolism. Trends Mol Med, 2010. 16(7): p. 329-35. 17.Jiang, X., H.L. Kenerson, and R.S. Yeung, Glucose deprivation in tuberous sclerosis complex-related tumors. Cell Biosci, 2011. 1: p. 34. 18.Rabenou, R.A. and H.W. Charles, Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma. AJR Am J Roentgenol, 2015. 205(2): p. 292-301. 19.Eijkemans, M.J., et al., Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Am J Kidney Dis, 2015. 66(4): p. 638-45. 20.Wang, C., et al., An update on recent developments in rupture of renal angiomyolipoma. Medicine (Baltimore), 2018. 97(16): p. e0497. 21.Metcalfe, S.A., Genetic counselling, patient education, and informed decision-making in the genomic era. Semin Fetal Neonatal Med, 2018. 23(2): p. 142-149. 22.Than, N.G. and Z. Papp, Ethical issues in genetic counseling. Best Pract Res Clin Obstet Gynaecol, 2017. 43: p. 32-49. 23.Martignoni, G., et al., Renal disease in adults with TSC2/PKD1 contiguous gene syndrome. Am J Surg Pathol, 2002. 26(2): p. 198-205. 24.Menko, F.H., et al., Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol, 2009. 10(12): p. 1199-206. 25.Dibble, C.C., et al., TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell, 2012. 47(4): p. 535-46. 26.Knudson, A.G., Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol, 1996. 122(3): p. 135-40. 27.Shibata, M., et al., TRIM45 negatively regulates NF-kappaB-mediated transcription and suppresses cell proliferation. Biochem Biophys Res Commun, 2012. 423(1): p. 104-9. 28.Berglund, E.C., A. Kiialainen, and A.C. Syvanen, Next-generation sequencing technologies and applications for human genetic history and forensics. Investig Genet, 2011. 2: p. 23. 29.Koboldt, D.C., et al., The next-generation sequencing revolution and its impact on genomics. Cell, 2013. 155(1): p. 27-38. 30.Li, H. and R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics, 2010. 26(5): p. 589-95. 31.Fokkema, I.F., et al., LOVD v.2.0: the next generation in gene variant databases. Hum Mutat, 2011. 32(5): p. 557-63. 32.Thorn, C.F., T.E. Klein, and R.B. Altman, PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol, 2013. 1015: p. 311-20. 33.Soussi, T., et al., High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. Hum Mutat, 2019. 40(5): p. 516-524. 34.Sherry, S.T., et al., dbSNP: the NCBI database of genetic variation. Nucleic Acids Res, 2001. 29(1): p. 308-11. 35.Sim, N.L., et al., SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res, 2012. 40(Web Server issue): p. W452-7. 36.Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 7(4): p. 248-9. 37.Numanagic, I., et al., Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun, 2018. 9(1): p. 828. 38.Richards, S., et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015. 17(5): p. 405-24. 39.Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform, 2009. 42(2): p. 377-81. 40.Girdea, M., et al., PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat, 2013. 34(8): p. 1057-65. 41.Wong, V., Study of the relationship between tuberous sclerosis complex and autistic disorder. J Child Neurol, 2006. 21(3): p. 199-204. 42.Moes, D.J., et al., Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT Pharmacometrics Syst Pharmacol, 2014. 3: p. e100. 43.Schoeppler, K.E., et al., The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant, 2014. 28(5): p. 590-7. 44.Urva, S., et al., A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol, 2013. 53(4): p. 444-50. 45.Meroni, G., Genomics and evolution of the TRIM gene family. Adv Exp Med Biol, 2012. 770: p. 1-9. 46.Zhang, J., et al., TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination. Cell Death Dis, 2017. 8(5): p. e2831. 47.Hung, C.C., et al., Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet, 2006. 7: p. 72. 48.Weinshilboum, R.M. and L. Wang, Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc, 2017. 92(11): p. 1711-1722. 49.Rahner, N. and V. Steinke, Hereditary cancer syndromes. Dtsch Arztebl Int, 2008. 105(41): p. 706-14. 50.Huynh, H., et al., Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Mol Cancer Ther, 2015. 14(5): p. 1224-35. 51.Yamamura, M., et al., Everolimus in pregnancy: Case report and literature review. J Obstet Gynaecol Res, 2017. 43(8): p. 1350-1352. 52.Seyam, R.M., et al., The Risks of Renal Angiomyolipoma: Reviewing the Evidence. J Kidney Cancer VHL, 2017. 4(4): p. 13-25. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73941 | - |
dc.description.abstract | 結節硬化症(Tuberous Sclerosis Complex; TSC)是一種因TSC1基因或TSC2基因發生變異,導致良性錯構瘤(hamartoma)的不正常增生,系統性影響全身多重器官的體染色體顯性遺傳疾病。由於結節硬化症是造成患者全面性的症狀發生,使得其衍伸而成的臨床照護問題亦日漸增長。因此,本研究針對結節硬化症患者,深入探討次世代定序(Next-Generation Sequencing; NGS)之基因診斷及整合性臨床照護問題,期許提升醫療照護品質與減輕患者及其家屬的長期苦痛。
本研究透過國立臺灣大學醫學院附設醫院之結節硬化症整合型門診,共納入532位受試者,總計為239個家族。根據結節硬化症整合門診各主治醫師評估及基因檢測結果,在239個家族中確認了180個家族中的先證者(proband)為結節硬化症;10個家族疑似為結節硬化症,但仍無法確診;49個家族則確認非結節硬化症患者。並針對同意加入研究案之患者進行臨床資料的收集、登錄、保存、彙整至結節硬化症整合型資料庫(Integrated Database of Tuberous Sclerosis Complex),同時本研究持續協助疑似結節硬化症患者,利用次世代定序進行基因確診;並透過藥物基因體檢測(pharmacogenomics testing),探討mTOR抑制劑在CYP3A4基因、ABCB1基因發生變異與患者藥物療效間進行探討;針對具有強烈遺傳性癌症家族史之結節硬化症家族,嘗試以全基因體定序(Whole Genome Sequencing; WGS)進行基因診斷;最後,利用案例報告的方式,深入探討結節硬化症女性患者腎血管平滑肌脂肪瘤(renal angiomyolipoma)之研究。 本研究目前透過次世代定序基因檢測之確診檢出率為89%。其中未檢出者有3%其致病性臨床意義不明(Variation of Unknown Significance; VUS)、;另8%則完全未發現懷疑變異點。而確診患者中有21%是TSC1基因發生變異;79%則是TSC2基因發生變異。以及30%是來自父母之遺傳,70%為自體新發生(de novo)的變異。最終根據上述統計,確認臺灣的結節硬化症流行病學現況,與各文獻所提出之比例未有明顯差異。 關於整合性臨床照護問題,本研究首次針對mTOR抑制劑透過藥物基因體檢測,進行CYP3A4基因、ABCB1基因變異與患者藥物療效間之探討。目前共納入64位患者,並予收集受試者之基本資料、血中藥物濃度、藥物劑量、其它用藥及症狀變化等以評估受試者之治療效果與用藥安全。最終協助兩位血中藥物濃度無法達到建議濃度範圍之患者,判定主要是因藥物交互作用所導致;而結節硬化症合併早發性(early-onsent)、多重原發性癌症(multiple primary cancers)之患者及其家族,本研究藉由周邊血液的全基因體定序,並透過共分離(co-segregation)分析方式偵測出具有致病性(pathogenic)之TRIM45基因剪接變異點。目前文獻雖提出TRIM45基因具有腫瘤抑制(tumor suppressor)功能,但相關研究仍知之甚少。因此期望藉由取得患者之病理組織,以次世代定序偵測第二致病變異(second hit),進一步確認結節硬化症與癌症之相關性。而若證實TSC基因帶有變異時,同時帶有癌症基因之變異,將加速腫瘤的增生促使癌症病程的發展,未來便可廣泛運用於具有癌症家族史或高危險群患者,協助定期追蹤及規劃治療策略;最後透過案例報告及與多專科團隊的討論、評估,為患有腎血管平滑肌脂肪瘤之女性患者,在妊娠前與妊娠期間、產後,建立一主要因應機制。並利用此次的案例報告經驗,使結節硬化症對於腎血管平滑肌脂肪瘤的醫療照護及遺傳諮詢更深入探討。 | zh_TW |
dc.description.abstract | Tuberous Sclerosis Complex (TSC) is a genetic disorder caused by pathogenic variants of the TSC1 or TSC2 genes, which could result in hamartomas or abnormal hyperplasia in multiple organs. It shows autosomal dominant inheritance. Considering the widespread manifestations in TSC patients, medical care for the patients becomes quite challenging. Therefore, this study aimed to provide genetic diagnosis taking advantage of next-generation sequencing (NGS), and also integrated clinical care.
Through the Integrated TSC Clinic of National Taiwan University Hospital, we recruited 532 subjects in 239 families into this project. After thorough evaluations based on the diagnostic crietria of TSC, 180 among the 239 probands were confirmed to be TSC patients, 10 were suspicious TSC cases, and 49 individuals were excluded as TSC patients. With the informed consents from the participants, we collected, registered, recorded, and consolidated their clinical data into the Integrated Database of Tuberous Sclerosis Complex, using a REDCap (Research Electronic Data Capture) system. For the suspected TSC patients, NGS could sometimes provide critical information for the correct diagnosis. For several patients showing unstable blood everolimus concentration, we performed a pharmacogenomics study (including the CYP3A4 and ABCB1 genes). For a TSC family carrying multiple cancers in multiple individuals, we conducted whole genome sequencing (WGS) of 4 individuals, attempting to identify the cancer-causing gene(s). We also investigated the clinical course of renal angiomyolipoma in women during pregnancy and after delivery. Of all the TSC probands receiving our NGS-based genetic testing, 89% were found to have pathogenic or likely pathogenic variants in TSC1 or TSC2, 3% with variation of unknown significance (VUS), and 8% were negative. Among the diagnosed patients, 21% of them were caused by TSC1 while the rest 79% were caused by TSC2. The disease-causing variants were inherited in 30% of probands, and were de novo mutations in 70% of the probands. According to the aforementioned statistics, this research has confirmed that the current epidemiological condition of TSC in Taiwan does not have a significant difference compared to the ratios presented in previous literature. For integrated clinic care, we investigated several aspects. First, we performed pharmacogenomic testing related to the mTOR inhibitor, everolimus, focusing on genetic variations of CYP3A4 and ABCB1 genes. Currently, there were 64 patients involved in this study with the permission to collect personal information, therapeutic drug monitoring, medicine dosage, other medication, symptom changes, and related data for evaluating the therapeutic effect and medication-use safety of the subjects. Second, for a TSC family with early-onsent and multiple primary cancers, we performed WGS in 4 individuals. After thorough analysis, we identified a splicing variation of the TRIM45 gene, which co-segregated in affected individuals. From the literature review, a handful of studies suggested that TRIM45 gene might possess a function of tumor suppressor; however, the data were not conclusive. We will continue working on the issue to clarify if TRIM45 indeed is the causing gene of those cancers in this family. This work might help to confirm TRIM45 as a genuine novel tumor suppressor gene. Third, this study presented a case series of female renal angiomyolipoma patients before, during, and after pregnancy. Through the observation, we hoped to develop an in-depth discussion about the healthcare and genetic counseling in female renal angiomyolipoma patients with TSC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:14:24Z (GMT). No. of bitstreams: 1 ntu-108-P06448004-1.pdf: 3773941 bytes, checksum: d3c2f020ec8654c616354387a1dc5148 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii Abstract v 第一章 研究背景與動機 1 1.1結節硬化症之疾病介紹 1 1.1.1歷史演進 1 1.1.2致病機轉 1 1.1.3疾病發生率與遺傳模式 2 1.2結節硬化症之臨床表徵 2 1.3結節硬化症之診斷標準 3 1.3.1臨床診斷標準 3 1.3.2基因診斷標準 4 1.4國立臺灣大學醫學院附設醫院之結節硬化症整合型門診及整合型資料庫 4 1.5結節硬化症之治療現況 5 1.5.1臨床治療方法 5 1.6結節硬化症之整合性臨床照護問題 6 1.6.1結節硬化症與癌症之相關性 6 1.6.2結節硬化症患者之腎血管平滑肌脂肪瘤破裂風險 7 1.7遺傳諮詢(Genetic Counselling) 8 1.8研究目的 9 第二章 研究方法 11 2.1研究對象 11 2.1.2受試者來源 11 2.1.4受試者同意書 12 2.2研究方法 12 2.2.1受試者DNA萃取 12 2.2.2偵測DNA品質 13 2.2.3次世代定序平台 13 2.2.4次世代定序(Next-Generation Sequencing; NGS) 15 2.2.5全基因體定序(Whole Genome Sequencing; WGS) 16 2.2.6基因變異點之致病性判讀 18 2.2.6聚合酶連鎖反應(PCR)與傳統定序(Sanger Sequencing) 19 2.3 REDCap (Research Electronic Data Capture)資料庫 19 第三章 研究結果 21 3.1次世代定序結果統計與分析 21 3.2結節硬化症整合型資料庫之管理現況 23 3.3 mTOR抑制劑與藥物基因體定序 24 3.3.1結節硬化症患者服用mTOR抑制劑之統計與分析 24 3.3.2藥物基因體定序結果與分析 28 3.4結節硬化症患者合併早發性、多重原發性癌症之研究 32 3.4.1案例報告 32 3.4.2全基因體定序結果與分析 35 3.5結節硬化症女性患者於妊娠期間之腎血管平滑肌脂肪瘤研究 37 3.5.1案例報告 37 3.5.2針對具有腎血管平滑肌脂肪瘤女性患者之全面性評估結果 42 3.6遺傳諮詢 43 3.6.1案例一 (TTSC00505) 43 3.6.2案例二 (TTSC00504) 45 3.6.3案例三 (TTSC00157) 46 第四章 討論 47 4.1臺灣結節硬化症之流行病學 47 4.2 mTOR抑制劑與精準醫療(Precision Medicine) 47 4.3 TSC基因變異與癌症基因間的相互作用 47 4.4腎血管平滑肌脂肪瘤於準備妊娠前、妊娠期間與產後之治療、照護方向 48 第五章 結論 50 參考文獻 51 附錄 55 附錄一、受試者同意書 55 (1)結節硬化症之基因體學、蛋白質體學及代謝體學研究 55 (2)建立結節硬化症之整合型資料庫 56 附錄二、TSC penpal 57 附錄三、TRIM45基因之探針設計 69 附錄四、KGGSeq之參數設定 70 附錄五、PCR primer 72 (1) TSC1 PCR primer 72 (2) TSC2 PCR primer 74 附錄六、TSC變異列表 77 附錄七、服用Everolimus之受試者列表 85 附錄八、TTF00222家族全基因體檢測之變異列表 87 | |
dc.language.iso | zh-TW | |
dc.title | 結節硬化症:次世代定序基因檢測以及整合性臨床照護 | zh_TW |
dc.title | Tuberous Sclerosis Complex (TSC): Next-Generation Sequencing (NGS)-based Genetic Testing and Integrated Clinical Care | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊偉勛(Wei-Shiung Yang),廖怡華(Yi-Hua Liao) | |
dc.subject.keyword | 結節硬化症,次世代定序,藥物基因體定序,全基因體定序,mTOR抑制劑,早發性癌症,多重原發性癌症,腎血管平滑肌脂肪瘤之破裂風險, | zh_TW |
dc.subject.keyword | Tuberous Sclerosis Complex (TSC),Next-generation sequencing (NGS),Whole genome sequencing (WGS),pharmacogenomics testing,early-onset cancer,multiple primary cancer,risk of renal angiomyolipoma rupture, | en |
dc.relation.page | 88 | |
dc.identifier.doi | 10.6342/NTU201903625 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。